MRK—Sotatercept phase-3 in PAH hits primary endpoint: https://finance.yahoo.com/news/merck-announces-positive-top-line-104500840.html Sotatercept is the drug MRK picked up in the $11.5B XLRN acquisitions last year (#msg-166156870).